StockData
Aclaris Therapeutics, Inc. logo

Aclaris Therapeutics, Inc. (ACRS) stock

ACRSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30138% above fair value
$3.50+0.12 (+3.55%)

Close on Nov 18, 2026Market cap $515.20MP/E –Yield –

Aclaris Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Aclaris Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$86.31M. For fiscal 2025 it was -$76.38M. The highest annual figure on record is -$5.26M in fiscal 2013.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$76.38M–
FY2024Dec 31, 2024-$141.93M–
FY2023Dec 31, 2023-$97.36M–
FY2022Dec 31, 2022-$89.85M–
FY2021Dec 31, 2021-$89.72M–
FY2020Dec 31, 2020-$50.91M–
FY2019Dec 31, 2019-$111.06M–
FY2018Dec 31, 2018-$84.78M–
FY2017Dec 31, 2017-$54.36M–
FY2016Dec 31, 2016-$48.57M–
FY2015Dec 31, 2015-$20.67M–
FY2014Dec 31, 2014-$8.53M–
FY2013Dec 31, 2013-$5.26M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$24.24M–
Q1 FY2026Mar 31, 2026-$22.19M–
Q4 FY2025Dec 31, 2025-$22.73M–
Q3 FY2025Sep 30, 2025-$17.15M–
Q2 FY2025Jun 30, 2025-$18.41M–
Q1 FY2025Mar 31, 2025-$18.08M–
Q4 FY2024Dec 31, 2024-$99.68M–
Q3 FY2024Sep 30, 2024-$10.47M–
Q2 FY2024Jun 30, 2024-$12.85M–
Q1 FY2024Mar 31, 2024-$18.93M–
Q4 FY2023Dec 31, 2023-$4.05M–
Q3 FY2023Sep 30, 2023-$31.58M–
Q2 FY2023Jun 30, 2023-$31.82M–
Q1 FY2023Mar 31, 2023-$29.92M–
Q4 FY2022Dec 31, 2022-$29.08M–
Q3 FY2022Sep 30, 2022-$20.87M–
Q2 FY2022Jun 30, 2022-$20.99M–
Q1 FY2022Mar 31, 2022-$18.91M–
Q4 FY2021Dec 31, 2021-$22.89M–
Q3 FY2021Sep 30, 2021-$20.30M–
Q2 FY2021Jun 30, 2021-$18.01M–
Q1 FY2021Mar 31, 2021-$28.53M–
Q4 FY2020Dec 31, 2020-$13.56M–
Q3 FY2020Sep 30, 2020-$10.47M–
Q2 FY2020Jun 30, 2020-$11.38M–
Q1 FY2020Mar 31, 2020-$15.51M–
Q4 FY2019Dec 31, 2019-$17.55M–
Q3 FY2019Sep 30, 2019-$22.86M–
Q2 FY2019Jun 30, 2019-$43.60M–
Q1 FY2019Mar 31, 2019-$27.05M–
Q4 FY2018Dec 31, 2018-$24.04M–
Q3 FY2018Sep 30, 2018-$21.34M–
Q2 FY2018Jun 30, 2018-$31.98M–
Q1 FY2018Mar 31, 2018-$30.95M–
Q4 FY2017Dec 31, 2017-$7.38M–
Q3 FY2017Sep 30, 2017-$18.76M–
Q2 FY2017Jun 30, 2017-$15.30M–
Q1 FY2017Mar 31, 2017-$12.93M–
Q4 FY2016Dec 31, 2016-$11.63M–
Q3 FY2016Sep 30, 2016-$10.81M–

More Aclaris Therapeutics figures

See a number that looks wrong?